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Clinical studies have demonstrated that circulating tumor cells (CTCs) are present in the
blood of cancer patients with known metastatic disease across the major types of epithe-
lial malignancies. Recent studies have shown that the concentration of CTCs in the blood
is prognostic of overall survival in breast, prostate, colorectal, and non-small cell lung can-
cer. This study characterizes CTCs identified using the high-definition (HD)-CTC assay in
an ovarian cancer patient with stage IIIC disease. We characterized the physical prop-
erties of 31 HD-CTCs and 50 normal leukocytes from a single blood draw taken just
prior to the initial debulking surgery. We utilized a non-interferometric quantitative phase
microscopy technique using brightfield imagery to measure cellular dry mass. Next we
used a quantitative differential interference contrast microscopy technique to measure
cellular volume. These techniques were combined to determine cellular dry mass den-
sity. We found that HD-CTCs were more massive than leukocytes: 33.6±3.2 pg (HD-CTC)
compared to 18.7±0.6 pg (leukocytes), p<0.001; had greater volumes: 518.3±24.5 fL
(HD-CTC) compared to 230.9±78.5 fL (leukocyte), p<0.001; and possessed a decreased
dry mass density with respect to leukocytes: 0.065±0.006 pg/fL (HD-CTC) compared to
0.085±0.004 pg/fL (leukocyte), p<0.006. Quantification of HD-CTC dry mass content and
volume provide key insights into the fluid dynamics of cancer, and may provide the ratio-
nale for strategies to isolate, monitor or target CTCs based on their physical properties.The
parameters reported here can also be incorporated into blood cell flow models to better
understand metastasis.
Keywords: circulating tumor cell, ovarian cancer, differential interference contrast, quantitative phase microscopy,
cellular mass, cellular volume, cellular density
INTRODUCTION
Ovarian cancer is the most lethal gynecological cancer and the fifth
leading cause of cancer death among women in the United States.
Over 90% of stage I patients with ovarian cancer can be cured with
the current standard of care: tumor resection followed by platinum
and taxane based chemotherapy. However, only 20% of ovarian
cancers are detected in stage I (Bast et al., 2009). This is due in
part to the anatomic location of the ovaries deep within the pelvis,
the absence of tumor-specific symptoms (Lim et al., 2012) and a
lack of effective serum markers that correlate with early disease
progression (Anderson et al., 2010; Urban et al., 2011). The devel-
opment of sensitive and specific diagnostic techniques for ovarian
cancer is thus imperative to enhance the treatment outcomes of
this disease. The enumeration and physical characterization of cir-
culating tumor cells (CTCs) represents a new strategy to monitor
the dynamics of tumor burden and potentially gain insight into the
hematogenous transport of CTCs to other locations in the body.
Clinical studies have demonstrated that CTCs are present in
the blood of cancer patients with known metastatic disease across
the major types of epithelial malignancies (Allard et al., 2004).
The concentration of CTCs in the blood is prognostic of overall
survival in ovarian (Poveda et al., 2011), breast (Cristofanilli et al.,
2004), prostate (Scher et al., 2009), colorectal (Cohen et al., 2008),
and non-small cell lung cancer (Nieva et al., 2012) and is predic-
tive of radiological response in some instances (Hayes et al., 2006;
Cristofanilli et al., 2004). Further, case reports suggest that CTCs
possess morphological features resembling the corresponding pri-
mary and/or metastatic lesions in breast (Marrinucci et al., 2007),
colorectal (Marrinucci et al., 2009a), and lung (Marrinucci et al.,
2009b) cancer. Together, these studies indicate that CTCs can be
used to survey primary and metastatic lesions through minimally
invasive peripheral blood draws or “fluid biopsies.”
While the morphology of CTCs is understood from the per-
spective of hematopathology, the physical properties of CTCs and
their potential correlation to disease progression, the physics of
hematogenous dissemination, and the processes governing arrest
in distant organs are ill-defined. The observation that epithelial
cells are less dense than red blood cells (RBCs) and tend to be
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large in comparison to hematopoetic cells has inspired the use
of density dependent enrichment via centrifugation (Rosenberg
et al., 2002) and size dependent selection through isolation by
size filtration (Vona et al., 2000). In this study, we sought to
measure the physical properties of CTCs without any fundamen-
tal assumptions regarding the value of these parameters. Hence,
the detection technique is independent of these parameters. We
utilized the high-definition (HD) CTC assay (Marrinucci et al.,
2012) which retains all nucleated cells from peripheral blood and
employs a rapid surface marker based fluorescence technique uti-
lizing laser scanning microscopy to identify cytokeratin positive,
CD45-negative, DAPI positive cells.
We analyzed 31 CTCs in a 66-year-old ovarian cancer patient
with stage IIIC disease. The cells were isolated from a blood draw
taken just prior to a debulking surgery. The HD-CTC assay is
compatible with high magnification optical microscopy, enabling
the use of non-interferometric quantitative phase microscopy (NI-
QPM) techniques to measure cellular dry mass and density; as well
as the use of differential interference contrast (DIC) microscopy
to measure cellular volume. We present a comparison of these bio-
physical metrics among CTCs and normal leukocyte populations
(N = 50) with the goal of understanding the cytophysical proper-
ties of cancer cells in the circulation. This study may provide the
rationale for future strategies to isolate, target, and monitor CTCs
using their physical properties.
MATERIALS AND METHODS
HD-CTC ENUMERATION AND CHARACTERIZATION
An ovarian cancer patient provided informed consent at Scripps
Clinic (La Jolla, CA, USA) as approved by the Institutional Review
Board. Eight milliliters of peripheral blood was collected in a rare
cell blood collection tube (Streck, Omaha, NE, USA) and processed
within 24 h after phlebotomy. HD-CTCs were identified accord-
ing to the published protocol, the sensitivity and specificity of
which is documented in Marrinucci et al. (2012). The technique
consists of a red blood cell lysis, after which nucleated cells are
attached as a monolayer to custom-made glass slides. These slides
are the same size as standard microscope slides and possess a pro-
prietary coating to ensure maximal retention of live cells. Slides
were subsequently incubated with antibodies against cytokeratins
(CK) 1, 4–8, 10, 13, 18, and 19 (Sigma); and CD45 with Alexa
647-conjugated secondary antibody (Serotec), nuclei were coun-
terstained with DAPI (Serotec). For HD-CTC identification, an
automated digital microscopy technique was used for fluorescence
imaging. Potential CTCs were located and identified by compu-
tational analysis of the resulting image data. Fluorescence images
of CTC candidates were then presented to a hematopathologist-
trained technical analyst for interpretation. Cells were classified
as HD-CTCs if they were CK-positive, CD45-negative, contained
an intact DAPI nucleus without identifiable apoptotic changes
or a disrupted appearance, and were morphologically distinct
from surrounding leukocytes. Cartesian coordinates for each HD-
CTC on a slide were generated from a fixed origin on that slide
and used to relocate the cells of interest for NI-QPM and DIC
measurements. Leukocytes located in the same field of view of
HD-CTCs were chosen at random to be quantitatively compared
to the HD-CTC population.
NON-INTERFEROMETRIC QUANTITATIVE PHASE MICROSCOPY TO
DETERMINE CELLULAR DRY MASS CONTENT
Due to their weak scattering and absorption properties over the
optical spectrum, cells appear semi-transparent when imaged
with standard brightfield microscopes. This low endogenous
contrast under brightfield is a result of the amplitude of the
waves traveling through the cell remaining relatively unchanged.
The thickness and spatially variable density of the cell how-
ever, contributes to appreciable phase lags of the transmit-
ted waves. This fact has inspired the utilization of phase as a
contrast mechanism in cellular imaging in modalities such as
phase contrast microscopy and DIC microscopy (Preza et al.,
2011).
Under the paraxial approximation, appropriate to weak index
contrast specimens such as cells, the phase, denoted φ (radian), is
defined as the sum of the relative refractive index of the sample
along the (typically unknown) height of the specimen, denoted
h(x, y) (µm) (Barer, 1952; Popescu, 2008)
φ
(
x , y
)
=
2pi
λ
∫ h(x ,y)
0
[
ncell
(
x , y , z
)− n0] dz (1)
λ is the wavelength of light used when determining phase. Inter-
estingly, Barer (1952) demonstrated that the dry mass content of a
cell could be extracted from quantitative measurements of phase
as a result of the cellular refractive index being linearly propor-
tional to the dry mass content of a cell. This technique has been
applied to the measurement cellular mass changes through the cell
cycle (Mir et al., 2011).
Denoting by C (g/mL) the dry mass density of a cell, and α the
specific refraction increment of the cell solids (∼0.2 mL/g), the
refractive index is dependent on the dry mass density as given by
ncell
(
x , y , z
)
= n0 + αC
(
x , y , z
)
. (2)
Defining the “projected” mass density as ρ
(
x , y
) =∫ h(x ,y)
0 C
(
x , y , z
)
dz (g/µm2), we can obtain ρ from phase by
substituting Eq. 2 into Eq. 1 to find
ρ = λφ
2piα
[g/µm2] (3)
Cell mass is then determined by integrating ρ over the area of
the cell. Equation 3 requires no assumptions regarding the uni-
formity of the refractive index or mass density along height of the
cell.
In the present investigation we utilize a computational tech-
nique based on the transport of intensity equation (TIE; Paganin
and Nugent, 1998) that relates axial intensity, denoted I (x, y, z),
variations to transverse phase variations
−2pi
λ
∂I
(
x , y , z
)
∂z
= ∇x ,y .
[
I
(
x , y , z
)∇x ,yφ (x , y , z)] . (4)
5x ,y denotes the two-dimensional gradient operator in the trans-
verse x, y (perpendicular to optical, z-axis) coordinates. The
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TIE enables the determination of phase from standard bright-
field intensity measurements acquired on a traditional microscope
employing a charge coupled device (CCD) camera.
The TIE phase measurement consists of an image acquisition
step and a post-processing procedure to determine phase. Low
numerical aperture (NA)∼0.3 Köhler illumination of the sample
is carried out on a Zeiss Axio Imager 2 microscope (Carl Zeiss
MicroImaging GmbH, Germany) with a green, λ= 540± 20 nm,
filter (Chroma Technology Corp., Bellows Falls, VT, USA). Three-
hundred through-focus brightfield intensity images of the sample
are obtained with a 0.1-µm axial step size under software con-
trol by SlideBook 5.5 (Intelligent Imaging Innovations, Denver,
CO, USA). The measured intensity is used to approximate the
axial derivative of the intensity, left hand side of Eq. 4. A Green
function technique is then utilized to solve for phase numeri-
cally (Frank et al., 2010) using a two-dimensional Fourier spectral
method. Lastly, Eq. 3 is used to determine the projected mass
density, ρ, from which the total cellular mass is determined by
integration over the area of the cell.
PREPARATION OF POLYSTYRENE SPHERES FOR NI-QPM VALIDATION
To explore the validity of the NI-QPM technique we prepared
polystyrene spheres whose phase properties are readily calculable.
Twenty microlitres of a 10% solution of polystyrene spheres (Poly-
sciences, Inc.) of diameter 0.11, 0.95, and 4.8µm were pipetted
separately on glass microscope slides (Fischer Scientific). Slides
FIGURE 1 |Transport of intensity based quantitative phase
microscopy validation over two orders of magnitude. (A,C,E)
Brightfield imagery of polystyrene spheres (n=1.597, λ=540 nm)
suspended in fluoromount G (n=1.4) with diameters of 0.11, 0.95, and
4.8 tm, respectively. (B,D,F) Corresponding transport of intensity based
quantitative phase maps. (G,H,I) demonstrate theoretical phase
profiles (dashed) for each polystyrene sphere with corresponding data
(circles) overlaid.
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FIGURE 2 | HD-CTC identification of ovarian cancer CTCs and
corresponding differential interference contrast (DIC) imagery.
(A,C) Immunofluorescent identification of HD-CTCs:
CK+CD45−DAPI+ and peripheral leukocytes: CK−CD45+DAPI+
(B,D) corresponding differential interference contrast images of the
same fields.
were air dried over night and then covered in Fluoromount G
(Southern Biotech) whereupon a number 1.5 glass coverslip (Carl
Zeiss MicroImaging) was placed overtop of the spheres. The sphere
samples were stored overnight at 4˚C to allow the Fluoromount G
to cure. Prior to imaging, the samples were allowed to return to
room temperature for 15 min.
DIFFERENTIAL INTERFERENCE CONTRAST BASED CELLULAR VOLUME
DETERMINATION
HD-CTCs were relocated and through-focus DIC imagery at×63
magnification, NA= 1.4, of each cell type was performed using a
Zeiss Axio Imager 2 microscope (Carl Zeiss MicroImaging GmbH,
Germany) with a green, λ= 540± 20 nm, filter (Chroma Tech-
nology Corp., Bellows Falls, VT, USA). Three-hundred planes
through the sample were acquired with an axial increment of
0.1µm. The microscope was under software control by Slide-
Book (Intelligent Imaging Innovations, Denver, CO, USA). Images
were post-processed using a custom written program in MAT-
LAB (The MathWorks, Inc., MA, USA). Post-processing consisted
of the application of a Hilbert transform to each en face DIC
image to ensure optimal contrast in image cube construction
(Arinson et al., 2000). This process enables thresholding of DIC
images at the cost of introducing some image blur along the axial
direction. This low frequency noise was eliminated with the appli-
cation of a high-pass filter to each sagittal plane of the image
volume. The relative refractive index of the mounting media and
immersion media (matching the cover glass) is low enough to
prevent appreciable elongation of images along the optical axis
(Rajadhyaksha et al., 1999). The cross sectional area of the cell in
distinct sagittal planes was determined using a Sobel-based edge
detection algorithm. Outlined sagittal planes of the cell separated
by 0.6µm were added together to obtain cellular volume. Each
voxel in the analysis corresponds to a diffraction limited vol-
ume of 0.28µm× 0.28µm× 0.35µm= 0.029 fL. Cellular area
was determined by outlining each cell in en face DIC images.
STATISTICAL ANALYSIS
The Jarque–Bera test was used to evaluate normality of all para-
meters. One-way analysis of variance with Bonferonni post hoc
analysis was used to assess statistical significance among para-
meters across multiple normally distributed cell parameters. The
Kruskal–Wallis test was used to assess significance among non-
normally distributed parameters. P-values of 0.05 or less were con-
sidered significant. All quantities presented as mean± standard
error of the mean unless otherwise noted.
RESULTS
TRANSPORT OF INTENSITY BASED QUANTITATIVE PHASE RETRIEVAL
METHOD MAINTAINS THE RESOLUTION OF THE DIFFRACTION LIMIT
AND IS STABLE OVER TWO ORDERS OF MAGNITUDE OF PHASE
To establish the accuracy of the TIE based phase retrieval algo-
rithm employed in this study, we performed phase retrieval
on polystyrene spheres (Polysciences, Inc., Warrington, PA,
USA; nsphere= 1.597, λ= 0.54µm) mounted in Fluoromount G
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(Southern Biotech, Birmingham, AL, USA; nFl.G= 1.4) on glass
slides. The reconstructed phase profile was compared to the the-
oretical phase profile for transmitted waves through a sphere of
radius r, given by
φ = 4pi
(
nsphere − nFl.G
)
λ
√
r2 − (x − x0)2. (5)
First we investigated the ability of the TIE to perform phase
retrieval at the diffraction limit of the microscope by evaluat-
ing the algorithm on 0.11µm diameter spheres subject to Köhler
illumination at an NA= 0.33. The measured resolution (×63,
NA= 1.4) was 0.38µm which agreed with the theoretical reso-
lution for a system: 1.22λ/(1.4+ 0.33). A higher illumination NA
could be used but at the expense of the validity of the TIE which
is posed under the paraxial approximation. In Figures 1A,B we
demonstrate the brightfield intensity and corresponding phase
map. Figure 1G compares the phase profile through the center
of the sphere to the theoretical profile. The TIE based phase had
a full-width at half maximum spatial resolution of 0.39µm. The
maximal phase shift of the sphere is 0.25± 0.03 radians, given the
manufacturer’s diameter variation of 0.012µm, and was measured
to be 0.26 by the TIE algorithm, within the manufacturing limits
of the sphere. The diffraction limit of the microscope prevented
any further information regarding the spatial dependence of the
phase profile (Figure 1G).
We next investigated the phase retrieval over two orders of mag-
nitude of the phase. Spheres of diameter 0.95 (Figures 1C,D,H)
and 4.75µm (Figures 1E,F,I) were investigated. The maximum
theoretical phase shifts induced by the spheres were 2.18± 0.18,
10.9± 1.06 rad. In all cases, the TIE phase retrieval was able to
recapitulate the theoretical values to within the manufacturing
constrains of the spheres (Figures 1D,F). As well, the TIE method
recapitulated the correct spatial phase profile inside the spheres
(Figures 1H,I). Deviations of the TIE phase measurement at the
edges of the spheres are to be expected from the discontinuity of
the refractive index at these locations.
HD-CTCs IDENTIFIED IN AN OVARIAN CANCER PATIENT HAVE
DECREASED DENSITIES, DECREASED MASS, INCREASED VOLUME AND
INCREASED AREA IN COMPARISON TO NORMAL PERIPHERAL
LEUKOCYTES
Having determined the validity of the TIE based NI-QPM algo-
rithm, we performed phase imaging on 31 HD-CTCs. The HD-
CTCs were identified in a single blood draw taken just prior to a
debulking surgery from a 66-year-old ovarian cancer patient with
stage IIIC disease. HD-CTCs were first identified by immunofluo-
rescence staining and subsequently relocated for label-free analysis
(Figure 2). Separate 25µm× 25µm× 30µm image cubes of
FIGURE 3 | Quantitative phase microscopy of circulating tumor cells;
comparison to differential interference contrast (DIC) and brightfield
microscopy. (A,D) Differential interference contrast imagery of
CK+CD45-DAPI+ HD-CTC5. (B,E) Corresponding bright field images. (C,F)
Quantitative phase microscopy images determined from the transport of
intensity equation analysis applied to brightfield through-focus imagery.
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individual cells comprised of 18,750,000 voxels were created under
brightfield and DIC settings (Figures 3A,B,D,E).
Brightfield image cubes were inputted into the TIE phase algo-
rithm to determine phase profiles for each cell (Figures 3C,F).
DIC image cubes were post-processed using a Hilbert transform
technique to enable Sobel-based edge detection to quantify cellular
volume.
HD-CTCs and leukocytes separated into distinct populations
in the mass-volume parameter space (Figure 4A) under the cur-
rent sampling condition of similar numbers of leukocytes and
HD-CTCs analyzed. We found that HD-CTCs were more mas-
sive than leukocytes (Table 1): 33.6± 3.2 pg (HD-CTC) compared
to 18.7± 0.6 pg (leukocytes), p< 0.001 (Figure 4C) and had
greater volumes (Table 1): 518.3± 24.5 fL (HD-CTC) compared
to 230.9± 78.5 fL (leukocyte), p< 0.001 (Figure 4D). HD-CTCs
were found to possess a decreased dry mass density with respect to
leukocytes (Table 1): 0.065± 0.006 pg/fL (HD-CTC) compared to
0.085± 0.004 pg/fL (leukocyte), p< 0.006 (Figure 4B). CTC areas
were larger than those of leukocytes (Table 1): 138.6± 8.1µm2
(CTC) compared to 51.8± 1.5µm2, p< 0.001 (Figure 4E).
DISCUSSION
Quantification of the biophysical properties of CTCs provides
insight into the physics of the fluid phase of cancer. Flow-
dependent interactions with RBCs in the vessels of the micro-
circulation give rise to the prevalence of less dense cells along
the periphery of the vessel wall (e.g., platelets, leukocytes), a phe-
nomenon known as margination (Goldsmith and Spain, 1984).
Oxygenated RBCs have a dry mass density of 0.3 pg/fL (Park
et al., 2008) by contrast, the leukocytes and HD-CTCs analyzed
in this study are roughly 3.5–4.5 times less dense than RBCs,
respectively (Table 1). The reduced dry mass density of leuko-
cytes and HD-CTCs in comparison to RBCs suggests that these
less dense cells may be physically trafficked to the vessel periphery
through margination in a similar manner. Proximity of CTCs to
the endothelium coupled with a large surface area could enhance
the kinetics for interactions with endothelial cells and aid in
promoting metastasis.
The label-free optical measurement of dry mass density and
volume of HD-CTCs and leukocytes quantifies the density over-
lap and volumetric differences among these cells. Area and volume
FIGURE 4 | Quantification of biophysical properties of ovarian
cancer HD-CTCs. (A) Scatter plot of cellular dry mass in pg
(abscissa) versus cellular volume in fL (ordinate). Quantitative phase
microscopy based mass measurements and differential interference
contrast based volume measurements were uncorrelated. (B)
Density box and whisker plot, (C) mass box and whisker, (D)
volume box and whisker, (E) area box whisker. *Denotes p<0.05
with respect to CTCs.
Table 1 | Biophysical properties of normal peripheral leukocytes and ovarian cancer associated HD-CTCs.
Cell type Area (mm2) Volume (fL) Mass (pg) Density (pg/fL) N
Leukocyte (WBC) 51.8±1.5 230.9±78.5 18.7±0.6 0.085±0.004 50
HD-CTC 138.6±8.1* 518.3±24.5* 33.6±3.2* 0.065±0.006* 31
Area was determined from outlining the boarder of cells using DIC imaging. Volume was determined using a Hilbert transform post-processing algorithm on through-
focusDIC image cubes.A non-interferometric quantitative phasemicroscopymethodwas used to determine cellular drymass content. Cellular densitywas determined
by dividing cellular mass by cellular volume. *Denotes p<0.05 with respect to leukocytes.
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were the most statistically significant features that separated the
populations from a physical standpoint. The dry mass density
values reported here (Table 1) demonstrate why CTC enrichment
using a density-based method is prone to leukocyte contamination
(Rosenberg et al., 2002): the overlap of leukocytes and HD-CTCs
makes the use of this parameter an unlikely means to separate the
two cell populations (Figure 4B). Volumetric differences among
these cell types demonstrate that isolation by size methods would
omit a fraction of leukocytes (assuming an 8µm diameter filter)
but again, at the cost of leukocyte contamination. One may be
tempted to make the filter size larger, allowing more leukocytes
to pass through the filter. This should result in reduced leukocyte
contamination but at the cost of omitting the potential CTC sub-
population that could overlap volumetrically with leukocytes. This
preliminary study in an Ovarian cancer patient demonstrated that
volume could separate the CTCs from the leukocyte population.
However, more investigations across patients, tumor types, and
treatment regimens are required to ensure members of the CTC
population would not be lost in the use of larger filter sizes in filtra-
tion enrichment approaches. The HD-CTC assay, an enrichment
free method, is an optimal tool to investigate the rationale for
biophysical based enrichment strategies for CTC detection and
lab-on-a-chip type characterizations.
The biophysical properties of HD-CTCs offer quantitative met-
rics with which to document potential changes in the CTC popula-
tion in response to therapeutics, disease progression, or interven-
tional surgeries. This label-free biophysical characterization can
be carried out in parallel with current efforts to understand the
genetic and proteomic composition of both the solid and fluid
phase of caner. Together, these complementary approaches might
aid in the search for targeted therapies.
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